CytoDyn chief executive Nader Pourhassan’s lucrative sale of company stock was confirmed in a regulatory filing Monday night. His explanation for profiting from the coronavirus epidemic — while urging outside investors to buy — remains a shifting and troubling narrative.
As previously reported, Pourhassan sold more than 4.82 million shares of Cytodyn stock on Thursday. What’s new is the disclosure that Pourhassan acquired the shares by exercising stock options and then selling the resulting CytoDyn stock. His take: $11.96 million.